Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPRA | P18433 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.95 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | TSHR | P16473 | 2/20 | 0.60 |
| ▸ | BLM | P54132 | 2/20 | 0.60 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | MPO | P05164 | 1/20 | 0.60 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | HTR1A | P08908 | 1/20 | 0.56 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.56 |
| ▸ | HTR2A | P28223 | 1/20 | 0.56 |
| ▸ | HTR2C | P28335 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2965137 | 1.00 | PTPRA (1.00) | PTPRACYP2C19KMT2AKDM4ELMNA | |
| SCHEMBL3519524 | 1.00 | PTPRA (1.00) | PTPRACYP2C19KMT2AKDM4ELMNA | |
| SCHEMBL30789181 | 1.00 | PTPRA (1.00) | PTPRACYP2C19KMT2AKDM4ELMNA | |
| SCHEMBL30381729 | 1.00 | PTPRA (1.00) | PTPRACYP2C19KMT2AKDM4ELMNA | |
| SCHEMBL1580111 | 0.90 | PTPRA (0.82) | PTPRACYP2C19KMT2AKDM4ELMNA | |
| SCHEMBL1580112 | 0.90 | PTPRA (0.82) | PTPRACYP2C19KMT2AKDM4ELMNA | |
| SCHEMBL22288108 | 0.86 | PTPRA (0.75) | PTPRACYP2C19KMT2AKDM4ELMNA | |
| SCHEMBL20931031 | 0.86 | PTPRA (0.75) | PTPRACYP2C19KMT2AKDM4ELMNA | |
| SCHEMBL22288107 | 0.86 | PTPRA (0.75) | PTPRACYP2C19KMT2AKDM4ELMNA | |
| SCHEMBL7380735 | 0.85 | PTPRA (0.73) | PTPRACYP2C19KMT2AKDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 793 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4034248-B1 | COMPOSITE BIOMARKER FOR CANCER THERAPY | BRISTOL MYERS SQUIBB CO (US) | 2026-05-20 | — | — | EP | claimed |
| WO-2024241086-A1 | PEGYLATED BOVINE INTERFERON LAMBDA AND METHODS OF USE THEREOF | AMBRX, INC. (US) | 2024-11-28 | — | — | WO | claimed |
| WO-2024215515-A1 | DRUG LINKERS AND ANTIBODY CONJUGATES THEREOF | AMBRX, INC. (US) | 2024-10-17 | — | — | WO | claimed |
| WO-2024178310-A1 | TROP2-DIRECTED ANTIBODY-DRUG CONJUGATES AND USES THEREOF | AMBRX, INC. (US) | 2024-08-29 | — | — | WO | claimed |
| WO-2024178360-A2 | AURISTATIN ANALOGS AND ANTIBODY CONJUGATES THEREOF | AMBRX, INC. (US) | 2024-08-29 | — | — | WO | claimed |
| CN-118207197-A | Immobilization of thermophilic archaea tryptophan synthase on magnetic bead-T4 phage capsid composite carrier | 江苏海洋大学 | 2024-06-18 | — | — | CN | claimed |
| US-20240084002-A1 | METHODS AND COMPOSITIONS UTILIZING IDO1-DEPENDENT VASCULARIZING CELLS FOR THE TREATMENT OF PATHOLOGICAL CONDITIONS INVOLVING NEOVASCULARIZATION | LANKENAU INSTITUTE FOR MEDICAL RESEARCH (US) | 2024-03-14 | — | — | US | claimed |
| EP-4255423-A1 | METHODS AND COMPOSITIONS UTILIZING IDO1-DEPENDENT VASCULARIZING CELLS FOR THE TREATMENT OF PATHOLOGICAL CONDITIONS INVOLVING NEOVASCULARIZATION | Lankenau Institute for Medical Research (US) | 2023-10-11 | — | — | EP | claimed |
| CN-116806149-A | Methods and compositions for treating pathological conditions involving neovascularization using IDO 1-dependent angiogenic cells | 兰肯瑙医学研究所 | 2023-09-26 | — | — | CN | claimed |
| US-11752131-B2 | Methods and pharmaceutical compositions for the treatment of obesity | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2023-09-12 | — | — | US | claimed |
| EP-1613308-A1 | NOVEL METHODS FOR THE TREATMENT OF CANCER | Lankenau Institute for Medical Research (US) | 2006-01-11 | — | — | EP | claimed |
| EP-1501918-A1 | ANTIGEN-PRESENTING CELL POPULATIONS AND THEIR USE AS REAGENTS FOR ENHANCING OR REDUCING IMMUNE TOLERANCE | Medical College Of Georgia Research Institute, Inc. (US) | 2005-02-02 | — | — | EP | claimed |
| WO-2004093871-A1 | NOVEL METHODS FOR THE TREATMENT OF CANCER | LANKENAU INSTITUTE FOR MEDICAL RESEARCH (US) | 2004-11-04 | — | — | WO | claimed |
| WO-2003087347-A1 | ANTIGEN-PRESENTING CELL POPULATIONS AND THEIR USE AS REAGENTS FOR ENHANCING OR REDUCING IMMUNE TOLERANCE | MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE, INC. (US) | 2003-10-23 | — | — | WO | claimed |
| US-20030194803-A1 | Antigen-presenting cell populations and their use as reagents for enhancing or reducing immune tolerance | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-10-16 | — | — | US | claimed |
| US-6482416-B2 | ALTERATION OF MACROPHAGE-INDUCED T CELL SUPPRESSION OR CONCENTRATION BY THE SELECTIVE ELIMINATION OR INCREASE OF TRYPTOPHAN BY ADMINISTERING AN ENZYME INHIBITOR OF INDOLE-AMINO 2,3-DEOXYGENASE; VIRICIDES; ABORTION; FERTILITY; | MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE, INC. | 2002-11-19 | — | — | US | claimed |
| US-20020155104-A1 | Regulation of T cell-mediated immunity by tryptophan | MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE, INC. | 2002-10-24 | — | — | US | claimed |
| US-6451840-B1 | Regulation of T cell-mediated immunity by tryptophan | MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE, INC. | 2002-09-17 | — | — | US | claimed |
| US-20010001040-A1 | Regulation of T cell-mediated immunity by tryptophan | MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE, INC. | 2001-05-10 | — | — | US | claimed |
| WO-1999029310-A2 | REGULATION OF T CELL-MEDIATED IMMUNITY BY TRYPTOPHAN AND ITS ANALOGS | MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE, INC. (US) | 1999-06-17 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240084002-A1 | METHODS AND COMPOSITIONS UTILIZING IDO1-DEPENDENT VASCULARIZING CELLS FOR THE TREATMENT OF PATHOLOGICAL CONDITIONS INVOLVING NEOVASCULARIZATION | IDO1, IDO2, TIE1 | PTPRA 2304/4885CYP2C19 4578/4885KMT2A 2568/4885 |
| US-11752131-B2 | Methods and pharmaceutical compositions for the treatment of obesity | IDO1, IDO2, GPR119 | PTPRA 2977/4885CYP2C19 313/4885KMT2A 1002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.